- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03258671
IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer
IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer: Results of a Randomised,Openlabel,Multicentre Study
This study is for patients with EFGR gene sensitive mutations diagnosed by pathology or cytology, having a course of chest radiotherapy treatment and molecular Target Therapy for the treatment of stage IV non-small cell lung cancer. Patients with non-small cell lung cancer have a risk of the tumour in the lung recurring or progressing after treatment.
In this study, the investigators aim to verify the following hypothesis:
- whether in combination with concurrent or concomitant EGFR-TKI regimen chemotherapy, Intensity Modulated Radiation Therapy can reduce the risk of the tumour in the lung recurring or progressing similarily.
- Intensity Modulated Radiation Therapy concomitant with EGFR-TKI has a better normal tissue dose/volume tolerance than concurrent regimen.
- the survival can be improved by using this new molecular Target-radiotherapy method.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Lu Bing, Director
- Telefonnummer: 86-18275356814
- E-post: ouyangww103173@163.com
Studiesteder
-
-
Guizhou
-
Guiyang, Guizhou, Kina, 550004
- The Affiliated Hospital Of Guizhou Medical University
-
Ta kontakt med:
- Lu Bing, MD
- Telefonnummer: 86-18275356814
- E-post: ouyangww103173@163.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologically or cytologically confirmed stage IV NSCLC[UICC 2017 8th edition] with known sensitive EGFR mutations(confirmed by tissue or blood).
- Have not received one or more prior treatments
- 18 to 80 years of age.ECOG performance status 0~2 or KPS≥60
- Have distant metastatic lesions≤5;and have clear consciousness when the metastatic sites were brain; and have no influence on pulmonary function when the metastatic sites were lung.
- Have no contraindications in radiotherapy, EGFR-TKI and chemotherapy
- Normal bone marrow and organ function as defined below:
Absolute neutrophil count ≥ 1,500/mcl Platelets ≥ 100,000/mcl Hemoglobin ≥ 9.0 g/dL Total bilirubin ≤ 2.0 x IULN AST (SGOT) / ALT (SGPT) ≤ 3.0 x IULN; if liver metastases, ≤ 5.0 x IULN Serum creatinine ≤ 1.5 x ULN LVEF ≥ 50% performed no more than 4 weeks prior to enrollment. FEV1>50%,mild-moderate pulmonary function dysfunction.
- Able to understand and willing to sign a Human Research Protection Office (HRPO) approved written informed consent document (or that of legally authorized representative, if applicable).
- With good compliance to the treatment and Follow-up
Exclusion Criteria:
- Evidence of small cell, large cell neuroendocrine or carcinoid histology.
- Non-stage IV NSCLC and ECOG performance status 3~5 or KPS<60
- Have a serious or uncontrolled medical condition that could compromise the patients' ability to adhere to the protocol.
- Malignant pleural effusion and pericardial effusion
- Uncontrolled intercurrent illness including, but not limited to, hypertension , diabetes mellitus ,ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant and/or breastfeeding: Patient must have a negative pregnancy test within 14 days of study entry.
- Have a secondary malignancy (except adequately treated non-melanomatous skin cancer, or other cancer such as in situ of the cervix. considered cured by surgical resection or radiation). Patients who have had another malignancy in the past but have been disease free for more than 5 years are eligible.
- A history of allergic reactions attributed to compounds of similar chemical or biologic composition to EGFR-TKI or other agents used in the study.
- With poor compliance
- The researchers consider it inappropriate to participate in the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Mutation+ concurrent
IMRT concurrent with EGFR-TKI on paticipants with known sensitive EGFR mutations.
|
·EGFR-TKI:gefitinib will be administered 250mg/d ivgtt qd; icotinib will be administered 150mg/d ivgtt tid;
High dose group:DTGTV=70Gy;
Low dose group:DTGTV=50Gy;
|
Eksperimentell: Mutation+ concomitant
IMRT concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.
|
·EGFR-TKI:gefitinib will be administered 250mg/d ivgtt qd; icotinib will be administered 150mg/d ivgtt tid;
High dose group:DTGTV=70Gy;
Low dose group:DTGTV=50Gy;
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Therapeutic efficacy of EGFR-TKI and concurrent/concomitant local RT in NSCLC patients.
Tidsramme: >4 weeks post treatment
|
Tumor Response will be evaluated using the RECIST system.
Modified WHO criteria will be used for measurement of tumors.
The irradiated lesion will be excluded from the assessment of response.
|
>4 weeks post treatment
|
Overall survival (OS)
Tidsramme: Up to 5 years
|
Overall survival is defined as the time interval from date of diagnosis to date of death from any cause
|
Up to 5 years
|
Progression-free survival (PFS)
Tidsramme: Up to 5 years
|
PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progressive disease (PD) = at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, appearance of one or more non-target lesion(s) and/or unequivocal progression of existing non-target lesions |
Up to 5 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Objective response rate(ORR)
Tidsramme: Up to 5 years
|
Partial response + complete response per RECIST 1.1 criteria Complete response (CR) = disappearance of all target lesions, non-target lesions, and normalization of tumor marker level Partial response (PR) = at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline of sum diameters |
Up to 5 years
|
Disease control rate (DCR)
Tidsramme: Up to 5 years
|
Percentage of patients who achieve complete response, partial response, or stable disease per RECIST 1.1 criteria. Complete response (CR) = disappearance of all target lesions, non-target lesions, and normalization of tumor marker level Partial response (PR) = at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline of sum diameters Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
Up to 5 years
|
Bivirkninger (toksisitet)
Tidsramme: Inntil 5 år
|
Beskrivelsene og karakterskalaene som finnes i de reviderte NCI Common Terminology Criteria for Adverse Events (CTCAE) versjon 4.0 vil bli brukt for all toksisitetsrapportering.
|
Inntil 5 år
|
Local regional progression-free survival(LRPFS)
Tidsramme: Time Frame: Up to 5 years
|
LRPFS is defined as the duration of time from start of treatment to time of progression or recurrence, whichever occurs first..The target lesions is only for primary tumor and regional positive lymph nodes. Progressive disease (PD) = at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, appearance of one or more target lesion(s) and/or unequivocal progression of existing target lesions. |
Time Frame: Up to 5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Lu Bing, Director, ouyangww103173@163.com
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CSWOG
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Karsinom, ikke-småcellet lunge
-
AHS Cancer Control AlbertaCross Cancer InstituteFullførtOmfattende Stage Small Cel Lung CancerCanada
-
Memorial Sloan Kettering Cancer CenterAktiv, ikke rekrutterendeB-celle lymfom | B-celle non-hodgkin lymfom | B Cell ALLForente stater
-
University of WashingtonNational Cancer Institute (NCI); National Comprehensive Cancer NetworkAvsluttetTilbakevendende mantelcellelymfom | Refraktært mantelcellelymfom | Ann Arbor Stage I Mantelcellelymfom | Ann Arbor Stage II mantelcellelymfom | Ann Arbor Stage III Mantle Cell Lymfom | Ann Arbor Stage IV Mantle Cell LymfomForente stater
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentTilbakefallende / Refractory Mantle Cell Lymfom (MCL)Kina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMantelcellelymfom | Blastoid Variant Mantle Cell Lymfom | Pleomorf variant av mantelcellelymfomForente stater
-
BeiGeneRekrutteringMantelcellelymfom | Residiverende mantelcellelymfom | Refractory Mantle Cell Lymfom (MCL)Forente stater, Kina, Israel, Belgia, Polen, Spania, Tyrkia, Brasil, Italia, Canada, Storbritannia, Frankrike, Tyskland, Argentina, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RekrutteringMantelcellelymfom | Blastoid Variant Mantle Cell Lymfom | Pleomorf variant av mantelcellelymfomForente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnn Arbor stadium I grad 1 follikulært lymfom | Ann Arbor stadium I grad 2 follikulært lymfom | Ann Arbor stadium II grad 1 follikulært lymfom | Ann Arbor stadium II grad 2 follikulært lymfom | Ann Arbor Stage IV B-celle non-Hodgkin lymfom | Ann Arbor Stage I B-celle non-Hodgkin lymfom | Ann Arbor... og andre forholdForente stater
-
Xiangyang No.1 People's HospitalQingdao Haier Biotechnology Co.,Ltd.Har ikke rekruttert ennåB-celle lymfom refraktært | B-celle lymfom Tilbakevendende | NK CellKina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)FullførtAnn Arbor stadium III grad 1 follikulært lymfom | Ann Arbor stadium III grad 2 follikulært lymfom | Ann Arbor Stage III Indolent voksen non-Hodgkin lymfom | Ann Arbor Stage IV Grad 1 Follikulært lymfom | Ann Arbor Stage IV Grad 2 Follikulært lymfom | Ann Arbor Stage IV Indolent voksen non-Hodgkin... og andre forholdForente stater
Kliniske studier på EGFR-TK Inhibitor
-
Fudan UniversityRekrutteringIkke-småcellet lungekreft | HjernemetastaserKina
-
Qingdao Central HospitalRekruttering
-
Xinqiao Hospital of ChongqingUkjentIkke småcellet lungekreftKina
-
Teikoku Seiyaku Co., Ltd.ClinSearch; CRM Biometrics GmbH; SocraTec R&D GmbH; SocraMetrics GmbH; Clinigen...Fullført
-
AGC Biologics S.p.A.FullførtHematologiske maligniteterItalia, Israel, Storbritannia, Tyskland, Hellas
-
Shanghai Pulmonary Hospital, Shanghai, ChinaUkjentIkke-småcellet lungekreft | EGFR-genmutasjon
-
Tosk, Inc.SIRO Clinpharm Private LimitedAktiv, ikke rekrutterende
-
Advanced Vision CareClinical Research Consultants, Inc.Rekruttering
-
The Methodist Hospital Research InstituteRekrutteringGlioblastom | Anaplastisk astrocytomForente stater
-
David Baskin MDCenter for Cell and Gene Therapy, Baylor College of MedicineRekrutteringGlioblastoma Multiforme | Astrocytom, grad IIIForente stater